Ashfield Capital Partners LLC lifted its stake in shares of Align Technology, Inc. (NASDAQ:ALGN) by 0.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 87,440 shares of the medical equipment provider’s stock after buying an additional 491 shares during the period. Align Technology comprises approximately 2.2% of Ashfield Capital Partners LLC’s investment portfolio, making the stock its 4th biggest position. Ashfield Capital Partners LLC owned approximately 0.11% of Align Technology worth $16,287,000 as of its most recent filing with the SEC.
Several other large investors also recently made changes to their positions in ALGN. Teachers Advisors LLC increased its holdings in shares of Align Technology by 4.9% during the first quarter. Teachers Advisors LLC now owns 70,197 shares of the medical equipment provider’s stock worth $8,052,000 after buying an additional 3,298 shares in the last quarter. NN Investment Partners Holdings N.V. increased its holdings in shares of Align Technology by 434.2% during the second quarter. NN Investment Partners Holdings N.V. now owns 2,671 shares of the medical equipment provider’s stock worth $401,000 after buying an additional 2,171 shares in the last quarter. State of Alaska Department of Revenue acquired a new position in shares of Align Technology during the second quarter worth $192,000. Chevy Chase Trust Holdings Inc. acquired a new position in shares of Align Technology during the second quarter worth $9,854,000. Finally, Mn Services Vermogensbeheer B.V. increased its holdings in shares of Align Technology by 541.2% during the second quarter. Mn Services Vermogensbeheer B.V. now owns 12,291 shares of the medical equipment provider’s stock worth $1,845,000 after buying an additional 10,374 shares in the last quarter. Institutional investors own 80.86% of the company’s stock.
In other Align Technology news, Director Greg J. Santora sold 7,700 shares of the company’s stock in a transaction on Tuesday, October 31st. The shares were sold at an average price of $238.95, for a total transaction of $1,839,915.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Julie Tay sold 3,500 shares of the company’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $253.00, for a total transaction of $885,500.00. Following the sale, the vice president now directly owns 12,213 shares in the company, valued at approximately $3,089,889. The disclosure for this sale can be found here. Insiders have sold 16,600 shares of company stock worth $4,031,567 in the last ninety days. Insiders own 1.60% of the company’s stock.
Shares of Align Technology, Inc. (ALGN) traded up $6.00 on Thursday, reaching $255.19. 542,109 shares of the company’s stock were exchanged, compared to its average volume of 1,007,690. The company has a market capitalization of $20,450.00, a PE ratio of 75.15, a P/E/G ratio of 2.43 and a beta of 1.41. Align Technology, Inc. has a twelve month low of $88.56 and a twelve month high of $257.60.
Align Technology (NASDAQ:ALGN) last issued its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $1.01 EPS for the quarter, beating the Zacks’ consensus estimate of $0.82 by $0.19. The business had revenue of $385.30 million for the quarter, compared to analysts’ expectations of $359.80 million. Align Technology had a net margin of 19.98% and a return on equity of 25.60%. The business’s quarterly revenue was up 38.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.63 earnings per share. research analysts forecast that Align Technology, Inc. will post 3.62 earnings per share for the current fiscal year.
Several research analysts have recently issued reports on the stock. Credit Suisse Group reiterated a “positive” rating and set a $261.00 price target (up from $209.00) on shares of Align Technology in a report on Thursday, November 9th. Zacks Investment Research raised shares of Align Technology from a “hold” rating to a “buy” rating and set a $227.00 price objective on the stock in a research note on Monday, October 30th. Leerink Swann reissued an “outperform” rating and issued a $250.00 price objective on shares of Align Technology in a research note on Friday, October 27th. Robert W. Baird reissued a “buy” rating and issued a $245.00 price objective on shares of Align Technology in a research note on Friday, October 27th. Finally, Stifel Nicolaus boosted their price objective on shares of Align Technology from $205.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, October 23rd. Eleven analysts have rated the stock with a buy rating, Align Technology currently has an average rating of “Buy” and a consensus price target of $219.18.
Align Technology Profile
Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.
Want to see what other hedge funds are holding ALGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Align Technology, Inc. (NASDAQ:ALGN).
Receive News & Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.